{
  "id": 20097503,
  "title": "Paysign: 3 Key Takeaways for Long-Term Investors",
  "url": "https://urgent.news/2026/11/15/paysign-3-key-takeaways-for-long-term-investors",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-15T02:15:32.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/earnings/takeaways/2026/11/14/paysign-3-key-takeaways-for-long-term-investors/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": null,
  "summary": "Paysign reported a 43% year-over-year revenue increase to $30.8 million in its third-quarter 2026 earnings call, driven by expansion in its pharmaceutical copay assistance business. The company's patient affordability solutions are proving to be a growth engine, with revenue in this segment growing 110% year-over-year to $16.6 million. Management highlighted the importance of protecting client budgets through dynamic business rules software, which insulates clients from costs that co-pay accumulators would otherwise absorb. With zero bank debt and $34.5 million in cash, Paysign is allocating capital to high-margin patient-assistance features while expanding its core processing operations.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Paysign: 3 Key Takeaways for Long-Term Investors",
        "url": "https://urgent.news/2026/11/15/paysign-3-key-takeaways-for-long-term-investors-20105887",
        "published": "2026-11-15T02:35:32.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}